Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia.
Pérez-Martínez AntonioMaría Vela CuencaJose L Fuster SolerItziar AstigarragaAntonia Pascual MartínezJose M Vagace ValeroHoi Y TongJaime Valentín QuirogaLucía Fernández CasanovaAdela Escudero LópezLuisa SisinniMiguel BlanquerIsabel Mirones AguilarBerta González MartínezAlberto M BorobiaAntonio Pérez-MartínezPublished in: BMJ open (2020)
EudraCT code: 2015-001901-15, ClinicalTrials.gov Identifier: NCT02763475.
Keyphrases
- phase ii
- clinical trial
- natural killer cells
- double blind
- open label
- stem cell transplantation
- liver failure
- study protocol
- placebo controlled
- respiratory failure
- intensive care unit
- bone marrow
- phase iii
- emergency department
- drug induced
- aortic dissection
- hematopoietic stem cell
- randomized controlled trial
- high dose
- hepatitis b virus
- mechanical ventilation
- low dose
- acute respiratory distress syndrome